| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vascular Biology |
From the Departments of Medicine (X.J., F.Y., H.T., D.L., J.K.R., R.E.R., W.D., X.Y., H.W.), Anesthesiology (R.M.B.), and Pharmacology (W.D.), Baylor College of Medicine, Houston, Tex; Michael E. DeBakey VA Medical Center (X.J., F.Y., H.T., D.L., R.E.R., W.D., H.W.), Houston, Tex; University of Pennsylvania School of Medicine (A.I.S.), Philadelphia, Pa.
Correspondence to Hong Wang, VA Medical Center, Baylor College of Medicine, 2002 Holcombe Blvd 109-129, Houston, TX 77030. E-mail hongw{at}bcm.tmc.edu
Objective A risk factor for cardiovascular disease, hyperhomocystinemia (HHcy), is associated with endothelial dysfunction. In this study, we examined the mechanistic role of HHcy in endothelial dysfunction.
Methods and Results Through the use of 2 functional models, aortic rings and intravital video microscopy of the cremaster, we found that arterial relaxation in response to the endothelium-dependent vessel relaxant, acetylcholine or the nitric oxide synthase (NOS) activator (A23187), was significantly impaired in cystathionine ß-synthase null (CBS/) mice. However, the vascular smooth muscle cell (VSMC) response to the nitric oxide (NO) donor (SNAP) was preserved in CBS/ mice. In addition, superoxide dismutase and catalase failed to restore endothelium-dependent vasodilatation. Endothelial nitric oxide synthase (eNOS) activity was significantly reduced in mouse aortic endothelial cells (MAECs) of CBS/ mice, as well as in Hcy-treated mouse and human aortic endothelial cells (HAECs). Hcy-mediated eNOS inhibitionwhich was not rescued by adenoviral transduction of superoxide dismutase and glutathione peroxidase, or by tetrahydrobiopterin, sepiapterin, and arginine supplementations in MAECwas associated with decreased protein expression and increased threonine 495 phosphorylation of eNOS in HAECs. Ultimately, a protein kinase C (PKC) inhibitor, GF109203X (GFX), reversed Hcy-mediated eNOS inactivation and threonine 495 phosphorylation in HAECs.
Conclusions These data suggest that HHcy impairs endothelial function and eNOS activity, primarily through PKC activation.
A risk factor for cardiovascular disease, hyperhomocystinemia (HHcy), is associated with endothelial dysfunction. In this study, we examined the mechanistic role of HHcy in endothelial dysfunction. Our data suggest that HHcy impairs endothelial function and eNOS activity, primarily through PKC activation.
Key Words: homocysteine endothelial function eNOS protein kinase C
This article has been cited by other articles:
![]() |
S. Dayal and S. R. Lentz Murine Models of Hyperhomocysteinemia and Their Vascular Phenotypes Arterioscler. Thromb. Vasc. Biol., September 1, 2008; 28(9): 1596 - 1605. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Dayal, R. N. Rodionov, E. Arning, T. Bottiglieri, M. Kimoto, D. J. Murry, J. P. Cooke, F. M. Faraci, and S. R. Lentz Tissue-specific downregulation of dimethylarginine dimethylaminohydrolase in hyperhomocysteinemia Am J Physiol Heart Circ Physiol, August 1, 2008; 295(2): H816 - H825. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. C. Looft-Wilson, B. S. Ashley, J. E. Billig, M. R. Wolfert, L. A. Ambrecht, and S. E. Bearden Chronic diet-induced hyperhomocysteinemia impairs eNOS regulation in mouse mesenteric arteries Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2008; 295(1): R59 - R66. [Abstract] [Full Text] [PDF] |
||||
![]() |
P.-Y. Chang, S.-C. Lu, C.-M. Lee, Y.-J. Chen, T. A. Dugan, W.-H. Huang, S.-F. Chang, W. S.L. Liao, C.-H. Chen, and Y.-T. Lee Homocysteine Inhibits Arterial Endothelial Cell Growth Through Transcriptional Downregulation of Fibroblast Growth Factor-2 Involving G Protein and DNA Methylation Circ. Res., April 25, 2008; 102(8): 933 - 941. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Baragetti, S. Raselli, A. Stucchi, V. Terraneo, S. Furiani, L. Buzzi, K. Garlaschelli, E. Alberghini, A. L. Catapano, and G. Buccianti Improvement of endothelial function in uraemic patients on peritoneal dialysis: a possible role for 5-MTHF administration Nephrol. Dial. Transplant., November 1, 2007; 22(11): 3292 - 3297. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z.-Y. Chen, G.-G. Feng, K. Nishiwaki, Y. Shimada, Y. Fujiwara, T. Komatsu, and N. Ishikawa Possible roles of neuropeptide Y Y3-receptor subtype in rat aortic endothelial cell proliferation under hypoxia, and its specific signal transduction Am J Physiol Heart Circ Physiol, August 1, 2007; 293(2): H959 - H967. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Long, L. G. Cook, G.-Y. Wu, and B. M. Mitchell Removal of Fkbp12/12.6 From Endothelial Ryanodine Receptors Leads to an Intracellular Calcium Leak and Endothelial Dysfunction Arterioscler. Thromb. Vasc. Biol., July 1, 2007; 27(7): 1580 - 1586. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Long, L. G. Cook, S. L. Hamilton, G.-Y. Wu, and B. M. Mitchell FK506 Binding Protein 12/12.6 Depletion Increases Endothelial Nitric Oxide Synthase Threonine 495 Phosphorylation and Blood Pressure Hypertension, March 1, 2007; 49(3): 569 - 576. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. R. Ansari, A. Nadeem, M. A. H. Talukder, S. Sakhalkar, and S. J. Mustafa Evidence for the involvement of nitric oxide in A2B receptor-mediated vasorelaxation of mouse aorta Am J Physiol Heart Circ Physiol, January 1, 2007; 292(1): H719 - H725. [Abstract] [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2005 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |